BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

...the CEO.Chronic disease company BioDelivery Sciences International Inc. (NASDAQ:BDSI) promoted CFO Terry Coelho to EVP and CFO.Cerevance Inc....
...company said. BC Staff SR One Surface Oncology Inc. Agenus Inc. AbCellera Biologics Inc. BioDelivery Sciences International Inc. Transcenta Holding Ltd. Dewpoint Therapeutics Cortexyme Inc. Cerevance Inc. Penrose...
BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

...access at Merck & Co. Inc. (NYSE:MRK), where he launched and commercialized Keytruda pembrolizumab.Neurology company Cerevance Inc....
...board, and brought on new board members Doron Birger and Ron Mayron.TARGETSTarget BC Staff Kadimastem Vivoryon Therapeutics Rinri Therapeutics Exacis Biotherapeutics Cerevance CRISPR...
BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

...With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has...
...markets dropping, we decided to close what we had right away.” Brad Margus, Cerevance Although Cerevance...
...unlikely to continue in Cerevance’s hands, Margus said. GV’s presence in the syndicate will allow Cerevance...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...are overwhelmed, neurodegeneration won’t be prioritized like cancer,” said Brad Margus, CEO of neurology company Cerevance Inc....
...lucky we have the capability to switch to remote monitoring, and remote site initiation visits.” Cerevance’s...
...to actually show the potential benefit of the drug that you are studying.” Margus said Cerevance...
BioCentury | Mar 20, 2020
Product Development

Back to China: companies see a safe haven emerging as the virus takes over the rest of the world

...our other biology from U.K. labs to Shanghai,” said Brad Margus, cofounder and CEO of Cerevance Inc....
BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

...way is protective, maybe it could be protective in all kinds of AD.” Brad Margus, Cerevance...
...genome that are shared among those mice. Brad Margus, co-founder and CEO of neurology company Cerevance Inc....
...Institutions Mentioned American Association for Cancer Research (AACR), Philadelphia, Pa. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cerevance Inc....
BioCentury | Oct 26, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

...Names Grant CEO" ). Two DDF portfolio companies, Alector Inc. (South San Francisco, Calif.) and Cerevance Inc....
BioCentury | Oct 24, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

...Names Grant CEO" ). Two DDF portfolio companies, Alector Inc. (South San Francisco, Calif.) and Cerevance Inc....
...six U.K. universities including the University of Cambridge, will encompass up to 700 researchers. Jennie Walters AL001 CVN424 Alector Inc. Cerevance Inc. Dementia...
BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...Woodlands, Texas). Neurology company Bionure Farma S.L. (Menlo Park, Calif.) hired Laurent Nguyen as CEO. Cerevance Inc....
BioCentury | Jun 23, 2018
Emerging Company Profile

Cerevance’s human element

...Lead program CVN058 is in Phase Ib testing to treat cognitive impairment in schizophrenia, and Cerevance...
...type, such as using dopamine agonists to address lost dopaminergic neurons in PD. In contrast, Cerevance’s...
...University. Cerevance has exclusive, worldwide rights to the technology and has further developed it in-house. Cerevance...
Items per page:
1 - 10 of 15
BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

...the CEO.Chronic disease company BioDelivery Sciences International Inc. (NASDAQ:BDSI) promoted CFO Terry Coelho to EVP and CFO.Cerevance Inc....
...company said. BC Staff SR One Surface Oncology Inc. Agenus Inc. AbCellera Biologics Inc. BioDelivery Sciences International Inc. Transcenta Holding Ltd. Dewpoint Therapeutics Cortexyme Inc. Cerevance Inc. Penrose...
BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

...access at Merck & Co. Inc. (NYSE:MRK), where he launched and commercialized Keytruda pembrolizumab.Neurology company Cerevance Inc....
...board, and brought on new board members Doron Birger and Ron Mayron.TARGETSTarget BC Staff Kadimastem Vivoryon Therapeutics Rinri Therapeutics Exacis Biotherapeutics Cerevance CRISPR...
BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

...With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has...
...markets dropping, we decided to close what we had right away.” Brad Margus, Cerevance Although Cerevance...
...unlikely to continue in Cerevance’s hands, Margus said. GV’s presence in the syndicate will allow Cerevance...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...are overwhelmed, neurodegeneration won’t be prioritized like cancer,” said Brad Margus, CEO of neurology company Cerevance Inc....
...lucky we have the capability to switch to remote monitoring, and remote site initiation visits.” Cerevance’s...
...to actually show the potential benefit of the drug that you are studying.” Margus said Cerevance...
BioCentury | Mar 20, 2020
Product Development

Back to China: companies see a safe haven emerging as the virus takes over the rest of the world

...our other biology from U.K. labs to Shanghai,” said Brad Margus, cofounder and CEO of Cerevance Inc....
BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

...way is protective, maybe it could be protective in all kinds of AD.” Brad Margus, Cerevance...
...genome that are shared among those mice. Brad Margus, co-founder and CEO of neurology company Cerevance Inc....
...Institutions Mentioned American Association for Cancer Research (AACR), Philadelphia, Pa. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cerevance Inc....
BioCentury | Oct 26, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

...Names Grant CEO" ). Two DDF portfolio companies, Alector Inc. (South San Francisco, Calif.) and Cerevance Inc....
BioCentury | Oct 24, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

...Names Grant CEO" ). Two DDF portfolio companies, Alector Inc. (South San Francisco, Calif.) and Cerevance Inc....
...six U.K. universities including the University of Cambridge, will encompass up to 700 researchers. Jennie Walters AL001 CVN424 Alector Inc. Cerevance Inc. Dementia...
BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...Woodlands, Texas). Neurology company Bionure Farma S.L. (Menlo Park, Calif.) hired Laurent Nguyen as CEO. Cerevance Inc....
BioCentury | Jun 23, 2018
Emerging Company Profile

Cerevance’s human element

...Lead program CVN058 is in Phase Ib testing to treat cognitive impairment in schizophrenia, and Cerevance...
...type, such as using dopamine agonists to address lost dopaminergic neurons in PD. In contrast, Cerevance’s...
...University. Cerevance has exclusive, worldwide rights to the technology and has further developed it in-house. Cerevance...
Items per page:
1 - 10 of 15